Aytu Biopharma Inc reports results for the quarter ended in June - Earnings Summary

Aytu Biopharma

28/09/2022 19:17

* Aytu Biopharma Inc  AYTU.OQ  reported a quarterly adjusted
loss
of 49 cents​​ per share for the quarter ended in June. The mean
expectation of two analysts for the quarter was for a loss of 37
cents per share.
    * Revenue rose 16.9% to $27.45 million from a year ago;
analysts
expected $25.50 million. 
    * Aytu Biopharma Inc's reported EPS for the quarter was a
loss
of 49 cents​.
    * The mean earnings estimate of analysts had risen by
about 26% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Aytu Biopharma Inc shares had fallen by 72.5% this
quarter and
lost 85.9% so far this year.
    * The company reported a quarterly loss of $17.7 million.
    * Wall Street's median 12-month price target for Aytu
Biopharma
Inc is $5.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data September
28 at 06:17 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.37          -0.49          Missed
 Mar. 31 2022      -0.41          -1.79          Missed
 Dec. 31 2021      -0.58          -0.44          Beat
 Sep. 30 2021      -0.49          -1.09          Missed